FDA’s authorization of a second COVID-19 booster shot for individuals 50 and over provides another opportunity for people to increase their level of protection against severe disease, hospitalization and death.
FDA’s authorization of a second COVID-19 booster shot for individuals 50 and over provides another opportunity for people to increase their level of protection against severe disease, hospitalization and death.
IDSA is heartened by the Administration’s recognition that antimicrobial resistance is a serious and urgent threat to patients and public health.
The Senate Health, Education, Labor and Pensions Committee is scheduled on March 15 to mark up the PREVENT Pandemics Act, a package of measures aimed at strengthening our nation’s preparedness for future health emergencies.
The Florida Surgeon General’s decision to recommend against COVID-19 vaccination for healthy children flies in the face of the best medical guidance and only serves to further sow distrust in vaccines that have proven to be the safest, most effective defense against severe COVID-19 disease, hospitalization and death.
IDSA and HIVMA strongly urge Texas Gov. Greg Abbott to stop government interference in the patient-health care provider relationship by withdrawing the order released last week that classifies medical treatment provided to transgender youth as “child abuse.”
The United States has reached an important milestone in ongoing efforts to combat COVID-19. As COVID-19 case rates and hospitalization rates in the United States continue to decline, IDSA supports the U.S. Centers for Disease Control and Prevention’s update to its COVID-19 community guidance.
Clinicians, scientists and public health leaders on the front lines of our response to the COVID-19 pandemic remain eager for new safe and effective therapies to treat the disease. The suffering and loss of life due to COVID-19 are tragic. We empathize with patients and their loved ones and are working to ensure the best care and outcomes for all.
IDSA’s journals, Clinical Infectious Diseases, The Journal of Infectious Diseases and Open Forum Infectious Diseases, are launching a call for applications for all qualified individuals with interest in joining the journals as associate editors.
IDSA is pleased to announce that Paul E. Sax, MD, FIDSA, has been selected as the next editor-in-chief of Clinical Infectious Diseases. Dr. Sax will succeed Robert T. Schooley, MD, on July 1, 2022, following Dr. Schooley’s years of outstanding service to the journal and the Society.
In recognition of the importance of inclusion, diversity, access and equity as long-term priorities and core values for IDSA, the Society’s Board of Directors recently approved the creation of a permanent IDA&E Committee.
The grant funds, which were awarded through the Foundation’s Microbial Pathogenesis in Alzheimer’s Disease Grant program, were dispersed among 11 researchers representing a wide range of research fields and institutions across the U.S.
The Omicron SARS-CoV-2 variant is more transmissible than earlier variants, which means that wearing the right mask is even more important.